Non-Cochrane · DTA · PM41590544
Comparative Meta-Analysis: Salivary, Plasma, and Serum miRNA Profiles for Oral Squamous Cell Carcinoma Detection.
Wijaya Arbi, Julia Vera, Soedarsono Nurtami, et al. · Journal of personalized medicine · 2026 · PubMed · doi:10.3390/jpm16010052
Findings
16 findings
| Population | ||||
|---|---|---|---|---|
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Salivary miRNA assays (RT-qPCR, microarray or NGS) | Healthy controls without disease | Pooled Specificity for OSCC detection Saliva, serum or plasma biofluid assays | Specificity 0.79 [0.70, 0.85] GRADE not reported 10 studies |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Salivary miRNA assays (RT-qPCR, microarray or NGS) | Healthy controls without disease | Pooled AUC (HSROC) for OSCC detection Saliva, serum or plasma biofluid assays | AUC (HSROC) 0.84 [0.80, 0.87] GRADE not reported 10 studies |
| Patients with histopathologically confirmed oral squamous cell carcinoma versus healthy controls | Salivary miRNA assays (single miRNAs or panels) | Histopathological diagnosis as reference standard (healthy controls) | Diagnostic odds ratio (lnDOR meta-analysis) Saliva | DOR 11.63 [4.57, 29.64] GRADE not reported 9 studies |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Salivary miRNA assays (RT-qPCR, microarray or NGS) | Healthy controls without disease | Pooled Sensitivity for OSCC detection Saliva, serum or plasma biofluid assays | Sensitivity 0.76 [0.68, 0.82] GRADE not reported 10 studies |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Serum miRNA assays (RT-qPCR, microarray or NGS) | Healthy controls without disease | Pooled Sensitivity for OSCC detection Saliva, serum or plasma biofluid assays | Sensitivity 0.82 [0.70, 0.90] GRADE not reported 6 studies |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Serum miRNA assays (RT-qPCR, microarray or NGS) | Healthy controls without disease | Pooled Specificity for OSCC detection Saliva, serum or plasma biofluid assays | Specificity 0.88 [0.75, 0.95] GRADE not reported 6 studies |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Serum miRNA assays (RT-qPCR, microarray or NGS) | Healthy controls without disease | Pooled AUC (HSROC) for OSCC detection Saliva, serum or plasma biofluid assays | AUC (HSROC) 0.91 [0.89, 0.94] GRADE not reported 6 studies |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Plasma miRNA assays (RT-qPCR, microarray or NGS) | Healthy controls without disease | Pooled Specificity for OSCC detection Saliva, serum or plasma biofluid assays | Specificity 0.79 [0.63, 0.89] GRADE not reported 3 studies |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Plasma miRNA assays (RT-qPCR, microarray or NGS) | Healthy controls without disease | Pooled Sensitivity for OSCC detection Saliva, serum or plasma biofluid assays | Sensitivity 0.77 [0.61, 0.88] GRADE not reported 3 studies |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Plasma miRNA assays (RT-qPCR, microarray or NGS) | Healthy controls without disease | Pooled AUC (HSROC) for OSCC detection Saliva, serum or plasma biofluid assays | AUC (HSROC) 0.85 [0.81, 0.89] GRADE not reported 3 studies |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Combined biofluid (saliva, serum, plasma) miRNA assays | Healthy controls without disease | Pooled AUC (HSROC) for OSCC detection Saliva, serum or plasma biofluid assays | AUC (HSROC) 0.86 [0.83, 0.89] GRADE not reported 19 studies · 2655 participants |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Combined biofluid (saliva, serum, plasma) miRNA assays | Healthy controls without disease | Pooled Sensitivity for OSCC detection Saliva, serum or plasma biofluid assays | Sensitivity 0.78 [0.72, 0.83] GRADE not reported 19 studies · 2655 participants |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Combined biofluid (saliva, serum, plasma) miRNA assays | Healthy controls without disease | Pooled diagnostic odds ratio for OSCC detection Saliva, serum or plasma biofluid assays | DOR 13.20 [8.10, 21.51] GRADE not reported 17 studies |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Combined biofluid (saliva, serum, plasma) miRNA assays | Healthy controls without disease | Pooled Specificity for OSCC detection Saliva, serum or plasma biofluid assays | Specificity 0.81 [0.75, 0.86] GRADE not reported 19 studies · 2655 participants |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Plasma miRNA assays | Salivary miRNA assays | Ratio of diagnostic odds ratios (meta-regression of lnDOR by biofluid) Saliva, serum or plasma biofluid assays | DOR ratio 1.13 [0.35, 3.72] GRADE not reported 17 studies |
| Patients with histopathologically confirmed oral squamous cell carcinoma (OSCC) | Serum miRNA assays | Salivary miRNA assays | Ratio of diagnostic odds ratios (meta-regression of lnDOR by biofluid) Saliva, serum or plasma biofluid assays | DOR ratio 1.38 [0.33, 5.80] GRADE not reported 17 studies |
Included primary studies 19
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Balakittnen 2024 A novel saliva-based miRNA profile to diagnose and predict oral cancer. PMID:38368395 | 2024 | 2 other reviews | not stated | not extracted yet |
| Garg 2023 Evaluation of Diagnostic Significance of Salivary miRNA-184 and miRNA-21 in Oral Squamous Cell Carcinoma and Oral Potentially Malignant… PMID:38015343 | 2023 | 2 other reviews | not stated | not extracted yet |
| Romani 2021 Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma. PMID:33456584 | 2021 | 2 other reviews | not stated | not extracted yet |
| Tarrad 2023 "Salivary LINC00657 and miRNA-106a as diagnostic biomarkers for oral squamous cell carcinoma, an observational diagnostic study". PMID:38087258 | 2023 | 2 other reviews | not stated | not extracted yet |
| Chen 2018 Diagnostic and prognostic value of serum miR-99a expression in oral squamous cell carcinoma. PMID:30223386 | 2018 | 1 other review | not stated | not extracted yet |
| Duz 2016 Identification of miR-139-5p as a saliva biomarker for tongue squamous cell carcinoma: a pilot study. PMID:26650483 | 2016 | 1 other review | not stated | not extracted yet |
| He 2020 Salivary exosomal miR-24-3p serves as a potential detective biomarker for oral squamous cell carcinoma screening. PMID:31704611 | 2020 | 1 other review | not stated | not extracted yet |
| Mehterov 2022 A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa. PMID:36531016 | 2022 | 1 other review | not stated | not extracted yet |
| Scholtz 2022 Salivary miR-31-5p, miR-345-3p, and miR-424-3p Are Reliable Biomarkers in Patients with Oral Squamous Cell Carcinoma. PMID:35215172 | 2022 | 1 other review | not stated | not extracted yet |
| Wan 2017 Salivary miRNA panel to detect HPV-positive and HPV-negative head and neck cancer patients. PMID:29245955 | 2017 | 1 other review | not stated | not extracted yet |
| Chang 2018 A Three-MicroRNA Signature as a Potential Biomarker for the Early Detection of Oral Cancer. PMID:29518940 | 2018 | this review only | not stated | not extracted yet |
| Karimi 2020 Evaluation of circulating serum 3 types of microRNA as biomarkers of oral squamous cell carcinoma; A pilot study. PMID:31483888 | 2020 | this review only | not stated | not extracted yet |
| Lu 2015 Combined determination of circulating miR-196a and miR-196b levels produces high sensitivity and specificity for early detection of oral… PMID:25485932 | 2015 | this review only | not stated | not extracted yet |
| Mazumder 2023 MiRNAs as non-invasive biomarkers in the serum of Oral Squamous Cell Carcinoma (OSCC) and Oral Potentially Malignant Disorder (OPMD)… PMID:36657275 | 2023 | this review only | not stated | not extracted yet |
| Nakamura 2021 Circulating microRNA Panel as a Potential Novel Biomarker for Oral Squamous Cell Carcinoma Diagnosis. PMID:33504017 | 2021 | this review only | not stated | not extracted yet |
| Piao 2023 A circulating microRNA panel as a novel dynamic monitor for oral squamous cell carcinoma. PMID:36737651 | 2023 | this review only | not stated | not extracted yet |
| Tachibana 2016 Circulating miR-223 in Oral Cancer: Its Potential as a Novel Diagnostic Biomarker and Therapeutic Target. PMID:27441818 | 2016 | this review only | not stated | not extracted yet |
| Wang 2021 MicroRNA-206 has a bright application prospect in the diagnosis of cases with oral cancer. PMID:34418889 | 2021 | this review only | not stated | not extracted yet |
| Zahran 2015 Salivary microRNAs in oral cancer. PMID:25784212 | 2015 | this review only | not stated | not extracted yet |
Overlap with other reviews
Reviews that include the same primary studies are not independent evidence. Shared counts match studies by PMID, DOI or NCT, and otherwise by author and year (a probable match). Only the non-Cochrane dental reviews have study lists, so overlap with Cochrane reviews is not counted yet.
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Patients with histopathologically confirmed oral squamous cell carcinoma | 1872 OSCC patients and 783 healthy controls (n=19 studies) |
| Intervention | Detection and quantification of miRNAs in saliva, plasma or serum (RT-qPCR, microarray or NGS) | Salivary miRNAs (10 studies, 13 datasets); serum miRNAs (6 studies, 8 datasets); plasma miRNAs (3 studies, 7 datasets); single miRNAs and panels |
| Comparison | Healthy controls without clinical evidence of disease | Healthy controls |
| Outcomes | Diagnostic accuracy: sensitivity, specificity, AUC, PPV, NPV, TP, FP, TN, FN | Pooled sensitivity, specificity, AUC (HSROC) by biofluid and combined; diagnostic odds ratio |
| Study designs | Observational diagnostic accuracy studies (case-control, cohort) | Case-control and cohort diagnostic accuracy studies (n=19) |
| Timing | Studies published January 2015 to December 2025 | Not specified |